Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy [PDF]
Molecules, 2020 Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five subtypes described. The interaction between SST and its receptors leads
Nicolas Lepareur +2 more
exaly +5 more sources
Meningiomas and Somatostatin Analogs: A Systematic Scoping Review on Current Insights and Future Perspectives [PDF]
International Journal of Molecular Sciences, 2023 Meningioma is the most frequent brain tumor, and the incidence is ever-increasing. Though often benign and slow growth, recurrence rates are substantial and today’s surgical and radiation-based treatment are not without complications.
Patricia Mjønes +2 more
exaly +4 more sources
Somatostatin Analogs in Clinical Practice: A Review [PDF]
International Journal of Molecular Sciences, 2020 Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of somatotropinomas, thyrotropinomas, and functioning and non-functioning gastroenteropancreatic neuroendocrine tumors.
Jersy Jair Cárdenas +1 more
exaly +3 more sources
225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic [PDF]
Pharmaceutics, 2023 The widespread use of peptide receptor radionuclide therapy (PRRT) represents a major therapeutic breakthrough in nuclear medicine, particularly since the introduction of 177Lu-radiolabeled somatostatin analogs. These radiopharmaceuticals have especially
Léa Rubira +4 more
doaj +2 more sources
Frontiers in Endocrinology, 2021 Neuroendocrine tumors overexpress somatostatin receptors, which serve as important and unique therapeutic targets for well-differentiated advanced disease.
Mayank Patel +5 more
doaj +2 more sources
DISSOCIATION OF BIOCHEMICAL AND TUMOR-SUPRESSIVE EFFECTS OF SOMATOSTATIN ANALOGS [PDF]
Alʹmanah Kliničeskoj Mediciny, 2016 Normalization of the growth hormone and IGF-1 levels during somatostatin analogs treatment usually is a predictor of somatotropinoma volume reduction.
A. V. Dreval’ +4 more
doaj +2 more sources
Insights into Structure-Activity Relationships of Somatostatin Analogs Containing Mesitylalanine [PDF]
Molecules, 2013 The non-natural amino acid mesitylalanine (2,4,6-trimethyl-L-phenylalanine; Msa) has an electron-richer and a more conformationally restricted side-chain than that of its natural phenylalanine counterpart.
Pablo Martín-Gago +12 more
doaj +3 more sources
Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors [PDF]
BMC Cancer, 2019 Background Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs.
Florian Bösch +10 more
doaj +2 more sources
A case of malignant insulinoma responsive to somatostatin analogs treatment [PDF]
BMC Endocrine Disorders, 2018 Background Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas the dimension (> 2 cm), CK19 status, the tumor staging and ...
Mariasmeralda Caliri +9 more
doaj +2 more sources
Somatostatin analogs in endothelial dysfunction. [PDF]
Am J Physiol Endocrinol MetabBarabutis N.
europepmc +3 more sources